Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Medical Decision Making
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0272989X07301822v1
27/3/327    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Noyes, K.
Right arrow Articles by Holloway, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Noyes, K.
Right arrow Articles by Holloway, R. G.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*LEVODOPA
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

The Implications of Using US-Specific EQ-5D Preference Weights for Cost-Effectiveness Evaluation

Katia Noyes, PhD, MPH

Department of Community and Preventive Medicine, University of Rochester School of Medicine, Rochester, New York, katia_noyes{at}urmc.rochester.edu

Andrew W. Dick, PhD

Department of Community and Preventive Medicine, University of Rochester School of Medicine, Rochester, New York, The RAND Corporation, Pittsburgh, Pennsylvania

Robert G. Holloway, MD, MPH

Department of Community and Preventive Medicine, University of Rochester School of Medicine, Rochester, New York, Department of Neurology, University of Rochester School of Medicine, Rochester, New York

Objective. The objective of this study is to examine the effect of country-specific EQ-5D preference weights on the cost-effectiveness (CE) of initial pramipexole versus levodopa strategy in patients with Parkinson disease (PD). Methods. A total of 301 subjects with PD were randomized to initial pramipexole or levodopa and followed every 3 months over a 4-year period. Subjects' health-related quality of life (HRQOL) was measured using EQ-5D, and their health preferences were calculated using both the UK and US sets of weights. The effectiveness of pramipexole was defined as the additional quality-adjusted life-years (QALY) gained compared to levodopa and was estimated as the area between the treatment-specific HRQOL profiles adjusted for baseline difference. Results. Using the original UK weights, the incremental effectiveness was 0.155 QALYs, which resulted in the incremental CE ratio (ICER) of $42,989/QALY and a probability that pramipexole was cost-effective relative to levodopa of 0.57, 0.77, and 0.82 when a QALY was valued at $50,000, $100,000, and $150,000, respectively. Using the US-specific weights resulted in lower incremental effectiveness (0.062 QALYs), higher ICER ($108,498/QALY), and a lower probability that pramipexole was cost-effective compared to levodopa at any valuation of QALY (0.23 for $50,000, 0.48 for $100,000, and 0.58 for $150,000). Conclusions. Country-specific preference weights in clinical-economic trials might have important effects on estimates of incremental cost-effectiveness. Using US preference weights rather than UK preference weights reduced the probability that pramipexole was cost-effective compared to levodopa.

Key Words: Key words: Parkinson disease • EQ-5D • quality of life • cost-effectiveness • pramipexole • levodopa. (Med Decis Making 2007;27:327—334)

This version was published on May 1, 2007

Medical Decision Making, Vol. 27, No. 3, 327-334 (2007)
DOI: 10.1177/0272989X07301822


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Med Decis MakingHome page
W. Miller
The Significance of Using US-Valued EQ-5D Health States for Comparative Effectiveness and Cost-Effectiveness Studies in US Populations
Med Decis Making, May 1, 2007; 27(3): 229 - 230.
[PDF]


Home page
Med Decis MakingHome page
L. B. Russell
Is All Cost-Effectiveness Analysis Local?
Med Decis Making, May 1, 2007; 27(3): 231 - 232.
[PDF]